Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis

References

• Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol. 2016;29(2):147–154.
   PubMed Web of Science ®Google Scholar
• Smits WK, Lyras D, Lacy DB, et al. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Clostridioides difficile infection [Internet]; [cited 2019 Aug 13]. Available from: https://www.cdc.gov/hai/organisms/cdiff/cdiff_infect.html
   Google Scholar
• Reveles KR, Lee GC, Boyd NK, et al. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010. Am J Infect Control. 2014;42(10):1028–1032.
   PubMed Web of Science ®Google Scholar
• Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539–1548.
   PubMed Web of Science ®Google Scholar
• DePestel DD, Aronoff DM. Epidemiology of Clostridium difficile infection. J Pharm Pr. 2013;26(5):464–475.
   PubMedGoogle Scholar
• Song JH, Kim YS. Recurrent Clostridium difficile infection: risk factors, treatment, and prevention. Gut Liver. 2019;13(1):16–24.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Reske K, Olsen M, et al. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study. BMC Infect Dis. 2014;14(1):306.
   PubMedGoogle Scholar
• Desai K, Gupta SB, Dubberke ER, et al. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect Dis. 2016;16(1):303.
   PubMedGoogle Scholar
• Rodrigues R, Barber GE, Ananthakrishnan AN. A comprehensive study of costs associated with recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol. 2017;38(2):196–202.
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(2):S88–S92.
   PubMedGoogle Scholar
• van Baal P, Morton A, Meltzer D, et al. Future unrelated medical costs need to be considered in cost effectiveness analysis. Eur J Health Econ. 2019;20(1):1–5.
   PubMed Web of Science ®Google Scholar
• Rappange DR, van Baal PHM, van Exel NJA, et al. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics. 2008;10:815–830.
   Google Scholar
• U.S. Bureau of Labor Statistics. Measuring price change in the CPI: medical care [Internet]; [cited 2020 Jan 9]. Available from: https://www.bls.gov/cpi/factsheets/medical-care.htm
   Google Scholar
• Nanwa N, Kendzerska T, Krahn M, et al. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol. 2015;110(4):511–519.
   PubMed Web of Science ®Google Scholar
• Shah DN, Aitken SL, Barragan LF, et al. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016;93(3):286–289.
   PubMed Web of Science ®Google Scholar
• Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18:21–27.
   PubMed Web of Science ®Google Scholar
• Abou Chakra CN, Pepin J, Sirard S, et al. Risk factors for recurrence, complications an mortality in Clostridium difficile infection: a systematic review. PLoS One. 2014;9(6):e98400.
   PubMed Web of Science ®Google Scholar
• Escobar GJ, Baker JM, Kipnis P, et al. Prediction of recurrenct Clostridium difficile infection using comprehensive electronic medical records in an integrated healthcare delivery system. Infect Control Hosp Epidemiol. 2017;38(10):1196–1203.
   PubMed Web of Science ®Google Scholar
• LaBarbera FD, Nikiforov I, Parvathenani A, et al. A prediction model for Clostridium difficile recurrence. J Comm Hosp Intern Med Perspect. 2015;5(1):26033.
   PubMed Web of Science ®Google Scholar
• van Beurden YH, Nezami S, Mulder CJJ, et al. Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics. Clin Microbiol Infect. 2018;24(1):85.e1–85.e4.
   Web of Science ®Google Scholar
• Zhang D, Prabhu VS, Marcella SW. Attributable healthcare resource utilization and costs for patients with primary and recurrent Clostridium difficile infection in the United States. Clin Infect Dis. 2018;66(9):1326–1332.
   PubMed Web of Science ®Google Scholar
• Freeman WJ, Weiss AJ, Heslin KC. Overview of U.S. hospital stays in 2016: variation by geographic region. HCUP Statistical Brief #246. December 2018. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/reports/statbriefs/sb246-Geographic-Variation-Hospital-Stays.pdf.
   Google Scholar
• Aitken SL, Joseph TB, Shah DN, et al. Healthcare resource utilization for recurrence Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One. 2014;9(7):e102848.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Tabak YP, Sievert DM, et al. Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals. Infect Control Hosp Epidemiol. 2011;32(7):649–655.
   PubMed Web of Science ®Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834.
   PubMed Web of Science ®Google Scholar
• Pechal A, Lin K, Allen S, et al. National age group trends in Clostridium difficile infection incidence and health outcomes in United States community hospitals. BMC Infect Dis. 2016;16(1):682.
   PubMedGoogle Scholar
• Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835–843.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Delholm-Lambertsen E, Hall BK, Jørgensen SMD, et al. Cost savings following faecal microbiota transplantation for recurrent Clostridium difficile infection. Ther Adv Gastroenterol. 2019;12:1–14.
   Web of Science ®Google Scholar
• McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20(01):43–50.
   PubMedGoogle Scholar